Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 4;68(9):e0046624.
doi: 10.1128/aac.00466-24. Epub 2024 Aug 13.

Ex vivo susceptibilities to ganaplacide and diversity in potential resistance mediators in Ugandan Plasmodium falciparum isolates

Affiliations

Ex vivo susceptibilities to ganaplacide and diversity in potential resistance mediators in Ugandan Plasmodium falciparum isolates

Oriana Kreutzfeld et al. Antimicrob Agents Chemother. .

Abstract

Novel antimalarials are urgently needed to combat rising resistance to available drugs. The imidazolopiperazine ganaplacide is a promising drug candidate, but decreased susceptibility of laboratory strains has been linked to polymorphisms in the Plasmodium falciparum cyclic amine resistance locus (PfCARL), acetyl-CoA transporter (PfACT), and UDP-galactose transporter (PfUGT). To characterize parasites causing disease in Africa, we assessed ex vivo drug susceptibilities to ganaplacide in 750 P. falciparum isolates collected in Uganda from 2017 to 2023. Drug susceptibilities were assessed using a 72-hour SYBR Green growth inhibition assay. The median IC50 for ganaplacide was 13.8 nM, but some isolates had up to 31-fold higher IC50s (31/750 with IC50 > 100 nM). To assess genotype-phenotype associations, we sequenced genes potentially mediating altered ganaplacide susceptibility in the isolates using molecular inversion probe and dideoxy sequencing methods. PfCARL was highly polymorphic, with eight mutations present in >5% of isolates. None of these eight mutations had previously been selected in laboratory strains with in vitro drug pressure and none were found to be significantly associated with decreased ganaplacide susceptibility. Mutations in PfACT and PfUGT were found in ≤5% of isolates, except for two frequent (>20%) mutations in PfACT; one mutation in PfACT (I140V) was associated with a modest decrease in susceptibility. Overall, Ugandan P. falciparum isolates were mostly highly susceptible to ganaplacide. Known resistance mediators were polymorphic, but mutations previously selected with in vitro drug pressure were not seen, and mutations identified in the Ugandan isolates were generally not associated with decreased ganaplacide susceptibility.

Keywords: PfACT; PfCARL; PfUGT; Plasmodium falciparum; antimalarial drugs; drug susceptibility; ganaplacide; malaria.

PubMed Disclaimer

Conflict of interest statement

Benjamin Blasco, Maelle Duffey, and Melanie Rouillier were employed by MMV, who funded part of the study.

Figures

Fig 1
Fig 1
Susceptibilities to ganaplacide and mutations in resistance mediators of Ugandan parasites. (A) IC50s of individual isolates (gray dots). The horizontal line shows the median and whiskers the interquartile range. Mean IC50s of control parasites 3D7 (red) and Dd2 (blue) are depicted as colored dots. Mutations in PfCARL (B) and PfACT (C) were observed in >5% of Ugandan P. falciparum isolates. Depicted are mutation frequencies of mixed (WT and mutant; blue) and mutant (red) isolates.
Fig 2
Fig 2
Spearman rank correlation between susceptibilities of Ugandan parasites to lumefantrine and ganaplacide. Blue dots depict results for single isolates. The black line demonstrates the linear regression.
Fig 3
Fig 3
Ganaplacide susceptibilities of Ugandan P. falciparum isolates with validated K13 mutations. Dots depict single isolates and bar graphs the median IC50s.

Similar articles

References

    1. World Health Organization . 2023. World malaria report 2023. Geneva: World Health Organization
    1. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455–467. doi:10.1056/NEJMoa0808859 - DOI - PMC - PubMed
    1. Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, Habimana RM, Rucogoza A, Moriarty LF, Sandford R, et al. . 2021. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis 21:1120–1128. doi:10.1016/S1473-3099(21)00142-0 - DOI - PMC - PubMed
    1. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, Opio W, Emoto S, Anywar DA, Kimura E, Palacpac NMQ, Odongo-Aginya EI, Ogwang M, Horii T, Mita T. 2021. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med 385:1163–1171. doi:10.1056/NEJMoa2101746 - DOI - PubMed
    1. Asua V, Conrad MD, Aydemir O, Duvalsaint M, Legac J, Duarte E, Tumwebaze P, Chin DM, Cooper RA, Yeka A, Kamya MR, Dorsey G, Nsobya SL, Bailey J, Rosenthal PJ. 2021. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. J Infect Dis 223:985–994. doi:10.1093/infdis/jiaa687 - DOI - PMC - PubMed

Publication types

MeSH terms